The Infinity War: How to Cope with Carbapenem-resistant Enterobacteriaceae.
10.3346/jkms.2018.33.e255
- Author:
Jin Hong YOO
1
Author Information
1. Division of Infectious Diseases, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Bucheon St. Mary's Hospital, Bucheon, Korea. jhyoo@catholic.ac.kr
- Publication Type:Review
- Keywords:
Carbapenems;
Carbapenemase;
Resistance;
Carbapenem-resistant Enterobacteriaceae
- MeSH:
Carbapenems;
Enterobacteriaceae*;
Fosfomycin;
Infection Control;
Korea;
Polymyxins
- From:Journal of Korean Medical Science
2018;33(40):e255-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Carbapenem-resistant Enterobacteriaceae (CRE) are now spread worldwide. In Korea, the number of CRE isolation is rapidly increasing, and impending endemicity is a concern. To cope well with CRE, thorough infection control, such as active surveillance, early detection, strict contact precaution, cleaning the environment, and antibiotic stewardship is very important. Therapeutic options include polymyxin, tigecycline, fosfomycin or the combination of them with carbapenem, which is currently the mainstay of treatment. In addition, various combination regimens with new carbapenemase inhibitors such as avibactam, vaborbactam, or relebactam, and other classes of antimicrobials such as plazomicin and siderophore cephalosporin are in the process of evaluation.
